 | • レポートコード：MRC2-11QY07954 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、110ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は心筋虚血治療薬のグローバル市場について調査・分析したレポートです。種類別（BAY-606583、CMK-103、DT-010、ヒューマニン、その他）市場規模、用途別（病院、診療所、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別心筋虚血治療薬の競争状況、市場シェア ・世界の心筋虚血治療薬市場：種類別市場規模 2015年-2020年（BAY-606583、CMK-103、DT-010、ヒューマニン、その他） ・世界の心筋虚血治療薬市場：種類別市場規模予測 2021年-2026年（BAY-606583、CMK-103、DT-010、ヒューマニン、その他） ・世界の心筋虚血治療薬市場：用途別市場規模 2015年-2020年（病院、診療所、その他） ・世界の心筋虚血治療薬市場：用途別市場規模予測 2021年-2026年（病院、診療所、その他） ・北米の心筋虚血治療薬市場分析：米国、カナダ ・ヨーロッパの心筋虚血治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの心筋虚血治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の心筋虚血治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの心筋虚血治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Baxalta Incorporated、Bayer AG、Cellmid Limited、CohBar, Inc.、Lixte Biotechnology Holdings, Inc.、NoNO, Inc.、Symic Biomedical, Inc.、Taxus Cardium Pharmaceuticals Group Inc.、ViroMed Co., Ltd. ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global Myocardial Ischemia Drugs Market
The global Myocardial Ischemia Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Myocardial Ischemia Drugs Scope and Market Size
Myocardial Ischemia Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Myocardial Ischemia Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Myocardial Ischemia Drugs market is segmented into
BAY-606583
CMK-103
DT-010
Humanin
Others
Segment by Application, the Myocardial Ischemia Drugs market is segmented into
Hospital
Clinic
Others
Regional and Country-level Analysis
The Myocardial Ischemia Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Myocardial Ischemia Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Myocardial Ischemia Drugs Market Share Analysis
Myocardial Ischemia Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Myocardial Ischemia Drugs business, the date to enter into the Myocardial Ischemia Drugs market, Myocardial Ischemia Drugs product introduction, recent developments, etc.
The major vendors covered:
Baxalta Incorporated
Bayer AG
Cellmid Limited
CohBar, Inc.
Lixte Biotechnology Holdings, Inc.
NoNO, Inc.
Symic Biomedical, Inc.
Taxus Cardium Pharmaceuticals Group Inc.
ViroMed Co., Ltd.
1 Study Coverage
1.1 Myocardial Ischemia Drugs Product Introduction
1.2 Market Segments
1.3 Key Myocardial Ischemia Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Myocardial Ischemia Drugs Market Size Growth Rate by Type
1.4.2 BAY-606583
1.4.3 CMK-103
1.4.4 DT-010
1.4.5 Humanin
1.4.6 Others
1.5 Market by Application
1.5.1 Global Myocardial Ischemia Drugs Market Size Growth Rate by Application
1.5.2 Hospital
1.5.3 Clinic
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Myocardial Ischemia Drugs Market Size, Estimates and Forecasts
2.1.1 Global Myocardial Ischemia Drugs Revenue 2015-2026
2.1.2 Global Myocardial Ischemia Drugs Sales 2015-2026
2.2 Global Myocardial Ischemia Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Myocardial Ischemia Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Myocardial Ischemia Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Myocardial Ischemia Drugs Competitor Landscape by Players
3.1 Myocardial Ischemia Drugs Sales by Manufacturers
3.1.1 Myocardial Ischemia Drugs Sales by Manufacturers (2015-2020)
3.1.2 Myocardial Ischemia Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Myocardial Ischemia Drugs Revenue by Manufacturers
3.2.1 Myocardial Ischemia Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Myocardial Ischemia Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Myocardial Ischemia Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Myocardial Ischemia Drugs Revenue in 2019
3.2.5 Global Myocardial Ischemia Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Myocardial Ischemia Drugs Price by Manufacturers
3.4 Myocardial Ischemia Drugs Manufacturing Base Distribution, Product Types
3.4.1 Myocardial Ischemia Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Myocardial Ischemia Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Myocardial Ischemia Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Myocardial Ischemia Drugs Market Size by Type (2015-2020)
4.1.1 Global Myocardial Ischemia Drugs Sales by Type (2015-2020)
4.1.2 Global Myocardial Ischemia Drugs Revenue by Type (2015-2020)
4.1.3 Myocardial Ischemia Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Myocardial Ischemia Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Myocardial Ischemia Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Myocardial Ischemia Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Myocardial Ischemia Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Myocardial Ischemia Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Myocardial Ischemia Drugs Market Size by Application (2015-2020)
5.1.1 Global Myocardial Ischemia Drugs Sales by Application (2015-2020)
5.1.2 Global Myocardial Ischemia Drugs Revenue by Application (2015-2020)
5.1.3 Myocardial Ischemia Drugs Price by Application (2015-2020)
5.2 Myocardial Ischemia Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Myocardial Ischemia Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Myocardial Ischemia Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Myocardial Ischemia Drugs Price Forecast by Application (2021-2026)
6 North America
6.1 North America Myocardial Ischemia Drugs by Country
6.1.1 North America Myocardial Ischemia Drugs Sales by Country
6.1.2 North America Myocardial Ischemia Drugs Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Myocardial Ischemia Drugs Market Facts & Figures by Type
6.3 North America Myocardial Ischemia Drugs Market Facts & Figures by Application
7 Europe
7.1 Europe Myocardial Ischemia Drugs by Country
7.1.1 Europe Myocardial Ischemia Drugs Sales by Country
7.1.2 Europe Myocardial Ischemia Drugs Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Myocardial Ischemia Drugs Market Facts & Figures by Type
7.3 Europe Myocardial Ischemia Drugs Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Myocardial Ischemia Drugs by Region
8.1.1 Asia Pacific Myocardial Ischemia Drugs Sales by Region
8.1.2 Asia Pacific Myocardial Ischemia Drugs Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Myocardial Ischemia Drugs Market Facts & Figures by Type
8.3 Asia Pacific Myocardial Ischemia Drugs Market Facts & Figures by Application
9 Latin America
9.1 Latin America Myocardial Ischemia Drugs by Country
9.1.1 Latin America Myocardial Ischemia Drugs Sales by Country
9.1.2 Latin America Myocardial Ischemia Drugs Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Myocardial Ischemia Drugs Market Facts & Figures by Type
9.3 Central & South America Myocardial Ischemia Drugs Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Myocardial Ischemia Drugs by Country
10.1.1 Middle East and Africa Myocardial Ischemia Drugs Sales by Country
10.1.2 Middle East and Africa Myocardial Ischemia Drugs Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Myocardial Ischemia Drugs Market Facts & Figures by Type
10.3 Middle East and Africa Myocardial Ischemia Drugs Market Facts & Figures by Application
11 Company Profiles
11.1 Baxalta Incorporated
11.1.1 Baxalta Incorporated Corporation Information
11.1.2 Baxalta Incorporated Description and Business Overview
11.1.3 Baxalta Incorporated Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Baxalta Incorporated Myocardial Ischemia Drugs Products Offered
11.1.5 Baxalta Incorporated Related Developments
11.2 Bayer AG
11.2.1 Bayer AG Corporation Information
11.2.2 Bayer AG Description and Business Overview
11.2.3 Bayer AG Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Bayer AG Myocardial Ischemia Drugs Products Offered
11.2.5 Bayer AG Related Developments
11.3 Cellmid Limited
11.3.1 Cellmid Limited Corporation Information
11.3.2 Cellmid Limited Description and Business Overview
11.3.3 Cellmid Limited Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Cellmid Limited Myocardial Ischemia Drugs Products Offered
11.3.5 Cellmid Limited Related Developments
11.4 CohBar, Inc.
11.4.1 CohBar, Inc. Corporation Information
11.4.2 CohBar, Inc. Description and Business Overview
11.4.3 CohBar, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.4.4 CohBar, Inc. Myocardial Ischemia Drugs Products Offered
11.4.5 CohBar, Inc. Related Developments
11.5 Lixte Biotechnology Holdings, Inc.
11.5.1 Lixte Biotechnology Holdings, Inc. Corporation Information
11.5.2 Lixte Biotechnology Holdings, Inc. Description and Business Overview
11.5.3 Lixte Biotechnology Holdings, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Lixte Biotechnology Holdings, Inc. Myocardial Ischemia Drugs Products Offered
11.5.5 Lixte Biotechnology Holdings, Inc. Related Developments
11.6 NoNO, Inc.
11.6.1 NoNO, Inc. Corporation Information
11.6.2 NoNO, Inc. Description and Business Overview
11.6.3 NoNO, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.6.4 NoNO, Inc. Myocardial Ischemia Drugs Products Offered
11.6.5 NoNO, Inc. Related Developments
11.7 Symic Biomedical, Inc.
11.7.1 Symic Biomedical, Inc. Corporation Information
11.7.2 Symic Biomedical, Inc. Description and Business Overview
11.7.3 Symic Biomedical, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Symic Biomedical, Inc. Myocardial Ischemia Drugs Products Offered
11.7.5 Symic Biomedical, Inc. Related Developments
11.8 Taxus Cardium Pharmaceuticals Group Inc.
11.8.1 Taxus Cardium Pharmaceuticals Group Inc. Corporation Information
11.8.2 Taxus Cardium Pharmaceuticals Group Inc. Description and Business Overview
11.8.3 Taxus Cardium Pharmaceuticals Group Inc. Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Taxus Cardium Pharmaceuticals Group Inc. Myocardial Ischemia Drugs Products Offered
11.8.5 Taxus Cardium Pharmaceuticals Group Inc. Related Developments
11.9 ViroMed Co., Ltd.
11.9.1 ViroMed Co., Ltd. Corporation Information
11.9.2 ViroMed Co., Ltd. Description and Business Overview
11.9.3 ViroMed Co., Ltd. Sales, Revenue and Gross Margin (2015-2020)
11.9.4 ViroMed Co., Ltd. Myocardial Ischemia Drugs Products Offered
11.9.5 ViroMed Co., Ltd. Related Developments
11.1 Baxalta Incorporated
11.1.1 Baxalta Incorporated Corporation Information
11.1.2 Baxalta Incorporated Description and Business Overview
11.1.3 Baxalta Incorporated Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Baxalta Incorporated Myocardial Ischemia Drugs Products Offered
11.1.5 Baxalta Incorporated Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Myocardial Ischemia Drugs Market Estimates and Projections by Region
12.1.1 Global Myocardial Ischemia Drugs Sales Forecast by Regions 2021-2026
12.1.2 Global Myocardial Ischemia Drugs Revenue Forecast by Regions 2021-2026
12.2 North America Myocardial Ischemia Drugs Market Size Forecast (2021-2026)
12.2.1 North America: Myocardial Ischemia Drugs Sales Forecast (2021-2026)
12.2.2 North America: Myocardial Ischemia Drugs Revenue Forecast (2021-2026)
12.2.3 North America: Myocardial Ischemia Drugs Market Size Forecast by Country (2021-2026)
12.3 Europe Myocardial Ischemia Drugs Market Size Forecast (2021-2026)
12.3.1 Europe: Myocardial Ischemia Drugs Sales Forecast (2021-2026)
12.3.2 Europe: Myocardial Ischemia Drugs Revenue Forecast (2021-2026)
12.3.3 Europe: Myocardial Ischemia Drugs Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Myocardial Ischemia Drugs Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Myocardial Ischemia Drugs Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Myocardial Ischemia Drugs Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Myocardial Ischemia Drugs Market Size Forecast by Region (2021-2026)
12.5 Latin America Myocardial Ischemia Drugs Market Size Forecast (2021-2026)
12.5.1 Latin America: Myocardial Ischemia Drugs Sales Forecast (2021-2026)
12.5.2 Latin America: Myocardial Ischemia Drugs Revenue Forecast (2021-2026)
12.5.3 Latin America: Myocardial Ischemia Drugs Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Myocardial Ischemia Drugs Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Myocardial Ischemia Drugs Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Myocardial Ischemia Drugs Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Myocardial Ischemia Drugs Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Myocardial Ischemia Drugs Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Myocardial Ischemia Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Myocardial Ischemia Drugs Market Segments
Table 2. Ranking of Global Top Myocardial Ischemia Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Myocardial Ischemia Drugs Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of BAY-606583
Table 5. Major Manufacturers of CMK-103
Table 6. Major Manufacturers of DT-010
Table 7. Major Manufacturers of Humanin
Table 8. Major Manufacturers of Others
Table 9. Global Myocardial Ischemia Drugs Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 10. Global Myocardial Ischemia Drugs Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 11. Global Myocardial Ischemia Drugs Sales by Regions 2015-2020 (K Pcs)
Table 12. Global Myocardial Ischemia Drugs Sales Market Share by Regions (2015-2020)
Table 13. Global Myocardial Ischemia Drugs Revenue by Regions 2015-2020 (US$ Million)
Table 14. Global Myocardial Ischemia Drugs Sales by Manufacturers (2015-2020) (K Pcs)
Table 15. Global Myocardial Ischemia Drugs Sales Share by Manufacturers (2015-2020)
Table 16. Global Myocardial Ischemia Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 17. Global Myocardial Ischemia Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Myocardial Ischemia Drugs as of 2019)
Table 18. Myocardial Ischemia Drugs Revenue by Manufacturers (2015-2020) (US$ Million)
Table 19. Myocardial Ischemia Drugs Revenue Share by Manufacturers (2015-2020)
Table 20. Key Manufacturers Myocardial Ischemia Drugs Price (2015-2020) (USD/Pcs)
Table 21. Myocardial Ischemia Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table 22. Manufacturers Myocardial Ischemia Drugs Product Type
Table 23. Date of International Manufacturers Enter into Myocardial Ischemia Drugs Market
Table 24. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 25. Global Myocardial Ischemia Drugs Sales by Type (2015-2020) (K Pcs)
Table 26. Global Myocardial Ischemia Drugs Sales Share by Type (2015-2020)
Table 27. Global Myocardial Ischemia Drugs Revenue by Type (2015-2020) (US$ Million)
Table 28. Global Myocardial Ischemia Drugs Revenue Share by Type (2015-2020)
Table 29. Myocardial Ischemia Drugs Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 30. Global Myocardial Ischemia Drugs Sales by Application (2015-2020) (K Pcs)
Table 31. Global Myocardial Ischemia Drugs Sales Share by Application (2015-2020)
Table 32. North America Myocardial Ischemia Drugs Sales by Country (2015-2020) (K Pcs)
Table 33. North America Myocardial Ischemia Drugs Sales Market Share by Country (2015-2020)
Table 34. North America Myocardial Ischemia Drugs Revenue by Country (2015-2020) (US$ Million)
Table 35. North America Myocardial Ischemia Drugs Revenue Market Share by Country (2015-2020)
Table 36. North America Myocardial Ischemia Drugs Sales by Type (2015-2020) (K Pcs)
Table 37. North America Myocardial Ischemia Drugs Sales Market Share by Type (2015-2020)
Table 38. North America Myocardial Ischemia Drugs Sales by Application (2015-2020) (K Pcs)
Table 39. North America Myocardial Ischemia Drugs Sales Market Share by Application (2015-2020)
Table 40. Europe Myocardial Ischemia Drugs Sales by Country (2015-2020) (K Pcs)
Table 41. Europe Myocardial Ischemia Drugs Sales Market Share by Country (2015-2020)
Table 42. Europe Myocardial Ischemia Drugs Revenue by Country (2015-2020) (US$ Million)
Table 43. Europe Myocardial Ischemia Drugs Revenue Market Share by Country (2015-2020)
Table 44. Europe Myocardial Ischemia Drugs Sales by Type (2015-2020) (K Pcs)
Table 45. Europe Myocardial Ischemia Drugs Sales Market Share by Type (2015-2020)
Table 46. Europe Myocardial Ischemia Drugs Sales by Application (2015-2020) (K Pcs)
Table 47. Europe Myocardial Ischemia Drugs Sales Market Share by Application (2015-2020)
Table 48. Asia Pacific Myocardial Ischemia Drugs Sales by Region (2015-2020) (K Pcs)
Table 49. Asia Pacific Myocardial Ischemia Drugs Sales Market Share by Region (2015-2020)
Table 50. Asia Pacific Myocardial Ischemia Drugs Revenue by Region (2015-2020) (US$ Million)
Table 51. Asia Pacific Myocardial Ischemia Drugs Revenue Market Share by Region (2015-2020)
Table 52. Asia Pacific Myocardial Ischemia Drugs Sales by Type (2015-2020) (K Pcs)
Table 53. Asia Pacific Myocardial Ischemia Drugs Sales Market Share by Type (2015-2020)
Table 54. Asia Pacific Myocardial Ischemia Drugs Sales by Application (2015-2020) (K Pcs)
Table 55. Asia Pacific Myocardial Ischemia Drugs Sales Market Share by Application (2015-2020)
Table 56. Latin America Myocardial Ischemia Drugs Sales by Country (2015-2020) (K Pcs)
Table 57. Latin America Myocardial Ischemia Drugs Sales Market Share by Country (2015-2020)
Table 58. Latin Americaa Myocardial Ischemia Drugs Revenue by Country (2015-2020) (US$ Million)
Table 59. Latin America Myocardial Ischemia Drugs Revenue Market Share by Country (2015-2020)
Table 60. Latin America Myocardial Ischemia Drugs Sales by Type (2015-2020) (K Pcs)
Table 61. Latin America Myocardial Ischemia Drugs Sales Market Share by Type (2015-2020)
Table 62. Latin America Myocardial Ischemia Drugs Sales by Application (2015-2020) (K Pcs)
Table 63. Latin America Myocardial Ischemia Drugs Sales Market Share by Application (2015-2020)
Table 64. Middle East and Africa Myocardial Ischemia Drugs Sales by Country (2015-2020) (K Pcs)
Table 65. Middle East and Africa Myocardial Ischemia Drugs Sales Market Share by Country (2015-2020)
Table 66. Middle East and Africa Myocardial Ischemia Drugs Revenue by Country (2015-2020) (US$ Million)
Table 67. Middle East and Africa Myocardial Ischemia Drugs Revenue Market Share by Country (2015-2020)
Table 68. Middle East and Africa Myocardial Ischemia Drugs Sales by Type (2015-2020) (K Pcs)
Table 69. Middle East and Africa Myocardial Ischemia Drugs Sales Market Share by Type (2015-2020)
Table 70. Middle East and Africa Myocardial Ischemia Drugs Sales by Application (2015-2020) (K Pcs)
Table 71. Middle East and Africa Myocardial Ischemia Drugs Sales Market Share by Application (2015-2020)
Table 72. Baxalta Incorporated Corporation Information
Table 73. Baxalta Incorporated Description and Major Businesses
Table 74. Baxalta Incorporated Myocardial Ischemia Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 75. Baxalta Incorporated Product
Table 76. Baxalta Incorporated Recent Development
Table 77. Bayer AG Corporation Information
Table 78. Bayer AG Description and Major Businesses
Table 79. Bayer AG Myocardial Ischemia Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 80. Bayer AG Product
Table 81. Bayer AG Recent Development
Table 82. Cellmid Limited Corporation Information
Table 83. Cellmid Limited Description and Major Businesses
Table 84. Cellmid Limited Myocardial Ischemia Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 85. Cellmid Limited Product
Table 86. Cellmid Limited Recent Development
Table 87. CohBar, Inc. Corporation Information
Table 88. CohBar, Inc. Description and Major Businesses
Table 89. CohBar, Inc. Myocardial Ischemia Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 90. CohBar, Inc. Product
Table 91. CohBar, Inc. Recent Development
Table 92. Lixte Biotechnology Holdings, Inc. Corporation Information
Table 93. Lixte Biotechnology Holdings, Inc. Description and Major Businesses
Table 94. Lixte Biotechnology Holdings, Inc. Myocardial Ischemia Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 95. Lixte Biotechnology Holdings, Inc. Product
Table 96. Lixte Biotechnology Holdings, Inc. Recent Development
Table 97. NoNO, Inc. Corporation Information
Table 98. NoNO, Inc. Description and Major Businesses
Table 99. NoNO, Inc. Myocardial Ischemia Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 100. NoNO, Inc. Product
Table 101. NoNO, Inc. Recent Development
Table 102. Symic Biomedical, Inc. Corporation Information
Table 103. Symic Biomedical, Inc. Description and Major Businesses
Table 104. Symic Biomedical, Inc. Myocardial Ischemia Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 105. Symic Biomedical, Inc. Product
Table 106. Symic Biomedical, Inc. Recent Development
Table 107. Taxus Cardium Pharmaceuticals Group Inc. Corporation Information
Table 108. Taxus Cardium Pharmaceuticals Group Inc. Description and Major Businesses
Table 109. Taxus Cardium Pharmaceuticals Group Inc. Myocardial Ischemia Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 110. Taxus Cardium Pharmaceuticals Group Inc. Product
Table 111. Taxus Cardium Pharmaceuticals Group Inc. Recent Development
Table 112. ViroMed Co., Ltd. Corporation Information
Table 113. ViroMed Co., Ltd. Description and Major Businesses
Table 114. ViroMed Co., Ltd. Myocardial Ischemia Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 115. ViroMed Co., Ltd. Product
Table 116. ViroMed Co., Ltd. Recent Development
Table 117. Global Myocardial Ischemia Drugs Sales Forecast by Regions (2021-2026) (K Pcs)
Table 118. Global Myocardial Ischemia Drugs Sales Market Share Forecast by Regions (2021-2026)
Table 119. Global Myocardial Ischemia Drugs Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 120. Global Myocardial Ischemia Drugs Revenue Market Share Forecast by Regions (2021-2026)
Table 121. North America: Myocardial Ischemia Drugs Sales Forecast by Country (2021-2026) (K Pcs)
Table 122. North America: Myocardial Ischemia Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 123. Europe: Myocardial Ischemia Drugs Sales Forecast by Country (2021-2026) (K Pcs)
Table 124. Europe: Myocardial Ischemia Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 125. Asia Pacific: Myocardial Ischemia Drugs Sales Forecast by Region (2021-2026) (K Pcs)
Table 126. Asia Pacific: Myocardial Ischemia Drugs Revenue Forecast by Region (2021-2026) (US$ Million)
Table 127. Latin America: Myocardial Ischemia Drugs Sales Forecast by Country (2021-2026) (K Pcs)
Table 128. Latin America: Myocardial Ischemia Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 129. Middle East and Africa: Myocardial Ischemia Drugs Sales Forecast by Country (2021-2026) (K Pcs)
Table 130. Middle East and Africa: Myocardial Ischemia Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 131. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 132. Key Challenges
Table 133. Market Risks
Table 134. Main Points Interviewed from Key Myocardial Ischemia Drugs Players
Table 135. Myocardial Ischemia Drugs Customers List
Table 136. Myocardial Ischemia Drugs Distributors List
Table 137. Research Programs/Design for This Report
Table 138. Key Data Information from Secondary Sources
Table 139. Key Data Information from Primary Sources
List of Figures
Figure 1. Myocardial Ischemia Drugs Product Picture
Figure 2. Global Myocardial Ischemia Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. BAY-606583 Product Picture
Figure 4. CMK-103 Product Picture
Figure 5. DT-010 Product Picture
Figure 6. Humanin Product Picture
Figure 7. Others Product Picture
Figure 8. Global Myocardial Ischemia Drugs Sales Market Share by Application in 2020 & 2026
Figure 9. Hospital
Figure 10. Clinic
Figure 11. Others
Figure 12. Myocardial Ischemia Drugs Report Years Considered
Figure 13. Global Myocardial Ischemia Drugs Market Size 2015-2026 (US$ Million)
Figure 14. Global Myocardial Ischemia Drugs Sales 2015-2026 (K Pcs)
Figure 15. Global Myocardial Ischemia Drugs Market Size Market Share by Region: 2020 Versus 2026
Figure 16. Global Myocardial Ischemia Drugs Sales Market Share by Region (2015-2020)
Figure 17. Global Myocardial Ischemia Drugs Sales Market Share by Region in 2019
Figure 18. Global Myocardial Ischemia Drugs Revenue Market Share by Region (2015-2020)
Figure 19. Global Myocardial Ischemia Drugs Revenue Market Share by Region in 2019
Figure 20. Global Myocardial Ischemia Drugs Sales Share by Manufacturer in 2019
Figure 21. The Top 10 and 5 Players Market Share by Myocardial Ischemia Drugs Revenue in 2019
Figure 22. Myocardial Ischemia Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 23. Global Myocardial Ischemia Drugs Sales Market Share by Type (2015-2020)
Figure 24. Global Myocardial Ischemia Drugs Sales Market Share by Type in 2019
Figure 25. Global Myocardial Ischemia Drugs Revenue Market Share by Type (2015-2020)
Figure 26. Global Myocardial Ischemia Drugs Revenue Market Share by Type in 2019
Figure 27. Global Myocardial Ischemia Drugs Market Share by Price Range (2015-2020)
Figure 28. Global Myocardial Ischemia Drugs Sales Market Share by Application (2015-2020)
Figure 29. Global Myocardial Ischemia Drugs Sales Market Share by Application in 2019
Figure 30. Global Myocardial Ischemia Drugs Revenue Market Share by Application (2015-2020)
Figure 31. Global Myocardial Ischemia Drugs Revenue Market Share by Application in 2019
Figure 32. North America Myocardial Ischemia Drugs Sales Growth Rate 2015-2020 (K Pcs)
Figure 33. North America Myocardial Ischemia Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 34. North America Myocardial Ischemia Drugs Sales Market Share by Country in 2019
Figure 35. North America Myocardial Ischemia Drugs Revenue Market Share by Country in 2019
Figure 36. U.S. Myocardial Ischemia Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 37. U.S. Myocardial Ischemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 38. Canada Myocardial Ischemia Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 39. Canada Myocardial Ischemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 40. North America Myocardial Ischemia Drugs Market Share by Type in 2019
Figure 41. North America Myocardial Ischemia Drugs Market Share by Application in 2019
Figure 42. Europe Myocardial Ischemia Drugs Sales Growth Rate 2015-2020 (K Pcs)
Figure 43. Europe Myocardial Ischemia Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 44. Europe Myocardial Ischemia Drugs Sales Market Share by Country in 2019
Figure 45. Europe Myocardial Ischemia Drugs Revenue Market Share by Country in 2019
Figure 46. Germany Myocardial Ischemia Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 47. Germany Myocardial Ischemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 48. France Myocardial Ischemia Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 49. France Myocardial Ischemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. U.K. Myocardial Ischemia Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 51. U.K. Myocardial Ischemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. Italy Myocardial Ischemia Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 53. Italy Myocardial Ischemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. Russia Myocardial Ischemia Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 55. Russia Myocardial Ischemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 56. Europe Myocardial Ischemia Drugs Market Share by Type in 2019
Figure 57. Europe Myocardial Ischemia Drugs Market Share by Application in 2019
Figure 58. Asia Pacific Myocardial Ischemia Drugs Sales Growth Rate 2015-2020 (K Pcs)
Figure 59. Asia Pacific Myocardial Ischemia Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 60. Asia Pacific Myocardial Ischemia Drugs Sales Market Share by Region in 2019
Figure 61. Asia Pacific Myocardial Ischemia Drugs Revenue Market Share by Region in 2019
Figure 62. China Myocardial Ischemia Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 63. China Myocardial Ischemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 64. Japan Myocardial Ischemia Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 65. Japan Myocardial Ischemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. South Korea Myocardial Ischemia Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 67. South Korea Myocardial Ischemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. India Myocardial Ischemia Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 69. India Myocardial Ischemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. Australia Myocardial Ischemia Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 71. Australia Myocardial Ischemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Taiwan Myocardial Ischemia Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 73. Taiwan Myocardial Ischemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Indonesia Myocardial Ischemia Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 75. Indonesia Myocardial Ischemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Thailand Myocardial Ischemia Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 77. Thailand Myocardial Ischemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Malaysia Myocardial Ischemia Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 79. Malaysia Myocardial Ischemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Philippines Myocardial Ischemia Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 81. Philippines Myocardial Ischemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Vietnam Myocardial Ischemia Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 83. Vietnam Myocardial Ischemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 84. Asia Pacific Myocardial Ischemia Drugs Market Share by Type in 2019
Figure 85. Asia Pacific Myocardial Ischemia Drugs Market Share by Application in 2019
Figure 86. Latin America Myocardial Ischemia Drugs Sales Growth Rate 2015-2020 (K Pcs)
Figure 87. Latin America Myocardial Ischemia Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 88. Latin America Myocardial Ischemia Drugs Sales Market Share by Country in 2019
Figure 89. Latin America Myocardial Ischemia Drugs Revenue Market Share by Country in 2019
Figure 90. Mexico Myocardial Ischemia Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 91. Mexico Myocardial Ischemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 92. Brazil Myocardial Ischemia Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 93. Brazil Myocardial Ischemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 94. Argentina Myocardial Ischemia Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 95. Argentina Myocardial Ischemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 96. Latin America Myocardial Ischemia Drugs Market Share by Type in 2019
Figure 97. Latin America Myocardial Ischemia Drugs Market Share by Application in 2019
Figure 98. Middle East and Africa Myocardial Ischemia Drugs Sales Growth Rate 2015-2020 (K Pcs)
Figure 99. Middle East and Africa Myocardial Ischemia Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 100. Middle East and Africa Myocardial Ischemia Drugs Sales Market Share by Country in 2019
Figure 101. Middle East and Africa Myocardial Ischemia Drugs Revenue Market Share by Country in 2019
Figure 102. Turkey Myocardial Ischemia Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 103. Turkey Myocardial Ischemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 104. Saudi Arabia Myocardial Ischemia Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 105. Saudi Arabia Myocardial Ischemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 106. U.A.E Myocardial Ischemia Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 107. U.A.E Myocardial Ischemia Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 108. Middle East and Africa Myocardial Ischemia Drugs Market Share by Type in 2019
Figure 109. Middle East and Africa Myocardial Ischemia Drugs Market Share by Application in 2019
Figure 110. North America Myocardial Ischemia Drugs Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 111. North America Myocardial Ischemia Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 112. Europe Myocardial Ischemia Drugs Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 113. Europe Myocardial Ischemia Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 114. Asia Pacific Myocardial Ischemia Drugs Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 115. Asia Pacific Myocardial Ischemia Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 116. Latin America Myocardial Ischemia Drugs Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 117. Latin America Myocardial Ischemia Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 118. Middle East and Africa Myocardial Ischemia Drugs Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 119. Middle East and Africa Myocardial Ischemia Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 120. Porter's Five Forces Analysis
Figure 121. Channels of Distribution
Figure 122. Distributors Profiles
Figure 123. Bottom-up and Top-down Approaches for This Report
Figure 124. Data Triangulation
Figure 125. Key Executives Interviewed
心筋虚血治療の世界市場（～2026年） Myocardial ischemia is a condition characterized by insufficient blood flow to the heart creating a paucity of oxygen leading to heart attacks. It is also known as cardiac ischemia and the blockage of coronary artery can cause abnormal heart rhythms. The Americas are the flag-bearer, the region is g…- 心筋灌流イメージング（MPI）検査の世界市場（～2026年） Myocardial perfusion imaging is an imaging device which work non-invasively to show the blood flow, myocardial perfusion imaging also known as nuclear cardiology test. The main function of this imaging to show the blood flow to muscle of heart or myocardium and to identify the absence or presence of…
- 心筋血行再建・修復・再生製品・治療法の世界市場（～2026年） Market Analysis and Insights: Global Myocardial Revascularization, Repair, and Regeneration Products and Therapies Market The global Myocardial Revascularization, Repair, and Regeneration Products and Therapies market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at…
- クリティカルリム虚血治療薬の世界市場（～2026年） Market Analysis and Insights: Global Critical Limb Ischemia Drug Market The global Critical Limb Ischemia Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Critical Limb Ischemia Drug Scope and Market Size Critical …
- 心筋梗塞治療薬の世界市場（～2026年） Market Analysis and Insights: Global Myocardial Infarction Drug Market The global Myocardial Infarction Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Myocardial Infarction Drug Scope and Market Size Myocardial I…